Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer-Reference-Cited by-同舟云学术

Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer

Published:2021-03-22 Issue: Volume: Page:
ISSN:0929-1903
Container-title:Cancer Gene Therapy
language:en
Short-container-title:Cancer Gene Ther

Author:

Rocconi Rodney P.,Stevens Erin E.,Bottsford-Miller Justin N.,Ghamande Sharad A.,Elder Jeffrey,DeMars Leslie L.,Munkarah Adnan,Aaron Phylicia^ORCID,Stanbery Laura,Wallraven Gladice,Bognar Ernest,Manley Meghan,Horvath Staci,Manning Luisa,Walter Adam,Galanis Evanthia,Herzog Thomas,Monk Bradley J.,Coleman Robert L.,Nemunaitis John^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Molecular Biology,Molecular Medicine

Link

http://www.nature.com/articles/s41417-021-00317-5.pdf

Reference45 articles.

1. Infante JR, Braiteh F, Emens L, Balmanoukian AS, Oaknin A, Wang Y, et al. Safety, clinical activity and biomarkers of atezolizumab (atezo) in advanced ovarian cancer (OC). Ann Oncol. 2016;27:871.

2. Preston CC, Goode EL, Hartmann LC, Kalli KR, Knutson KL. Immunity and immune suppression in human ovarian cancer. Immunotherapy. 2011;3:539–56.

3. Ino K. Indoleamine 2,3-dioxygenase and immune tolerance in ovarian cancer. Curr Opin Obstet Gynecol. 2011;23:13–8.

4. Tondini E, Arakelian T, Oosterhuis K, Camps M, van Duikeren S, Han W. et al. A poly-neoantigen DNA vaccine synergizes with PD-1 blockade to induce T cell-mediated tumor control. Oncoimmunology. 2019;8:1652539. https://doi.org/10.1080/2162402X.2019.1652539.

5. Wada S, Jackson CM, Yoshimura K, Yen H-R, Getnet D, Harris TJ, et al. Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer. J Transl Med. 2013;11:89.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and Prospects of Furin Inhibitors for Therapeutic Applications;International Journal of Molecular Sciences;2024-08-24

2. Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapy;Future Oncology;2024-08-05

3. Navigating immunotherapy for ovarian cancer: current landscape and future perspectives;Journal of Cancer Metastasis and Treatment;2024-06-26

4. Homologous recombination proficient subtypes of high-grade serous ovarian cancer: treatment options for a poor prognosis group;Frontiers in Oncology;2024-06-04

5. Transformers meets neoantigen detection: a systematic literature review;Journal of Integrative Bioinformatics;2024-06-01